新天药业(002873) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥969,844,472.18, representing a 29.15% increase compared to ¥750,946,390.31 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥100,605,308.02, a 35.76% increase from ¥74,103,210.31 in 2020[20]. - The net profit after deducting non-recurring gains and losses was ¥93,839,366.09, up 32.21% from ¥70,977,065.18 in 2020[20]. - The basic earnings per share for 2021 was ¥0.6193, a 34.48% increase from ¥0.4605 in 2020[20]. - The total operating revenue for 2021 was ¥969,844,472.18, representing a year-on-year increase of 29.15% compared to ¥750,946,390.31 in 2020[59]. - The main business revenue accounted for ¥968,695,455.00, which is 99.88% of total revenue, with a year-on-year growth of 29.13%[62]. - The gynecological product category generated ¥686,491,923.90, making up 70.78% of total revenue, with a growth rate of 31.83%[59]. - The gross profit margin for the main business was 79.28%, slightly up by 1.27% from the previous year[62]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[132]. - The company plans to set a revenue guidance of 1.5 billion RMB for the next fiscal year, projecting a growth rate of 25%[132]. Cash Flow and Investments - The net cash flow from operating activities decreased by 29.28% to ¥124,300,304.12 from ¥175,767,527.16 in 2020[20]. - The total cash inflow from operating activities increased by 19.92% to ¥1,002,079,539.69 in 2021 compared to ¥835,614,919.37 in 2020[73]. - Investment cash inflow surged by 93.15% to ¥553,082,000.00 in 2021, up from ¥286,351,416.78 in 2020[74]. - Financing cash inflow dropped by 47.07% to ¥300,811,607.40 in 2021, compared to ¥568,300,000.00 in 2020[74]. - The total amount of capitalized R&D investment decreased by 43.76% to ¥8,512,930.57 in 2021 from ¥15,135,456.00 in 2020[71]. - The company has allocated RMB 8,000 million to purchase wealth management products and RMB 3,000 million to temporarily supplement working capital[88]. - The company reported a usage rate of 34.83% for the raised funds, indicating that a significant portion remains unutilized[87]. - The company has committed to using the remaining funds from terminated projects for new initiatives, specifically the traditional Chinese medicine formula granule project[92]. Research and Development - The company has established three major R&D bases in Shanghai and Guiyang, forming a systematic R&D structure[45]. - The company has developed three new traditional Chinese medicine products that have completed Phase III clinical trials, with a total of 445 provincial standard varieties of traditional Chinese medicine formula granules and 60 national standard filings[52]. - Research and development expenses increased by 53.26% to ¥20,376,605.27, reflecting a focus on enhancing product offerings[69]. - The company emphasizes a "production generation, reserve generation, development generation" approach in its R&D strategy for traditional Chinese medicine[43]. - The company is committed to enhancing its research and development efforts to drive innovation in its product offerings[122]. Market and Product Development - The company has achieved a market scale of over 100 million for multiple key products, including Kuntai Capsule and Kushi Gel[35]. - The company plans to enhance market promotion for its exclusive products, aiming to expand market share and attract innovative talent[36]. - The company aims to strengthen the promotion of existing major products and enhance sales team construction, with a focus on expanding the OTC market and increasing online sales investment[102]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[132]. - The company plans to produce new products such as Re-Lin-Qing Syrup and Xie-Yu-Jiang-Zhi Capsule in the future[46]. Corporate Governance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations[111]. - The board of directors consists of three independent directors, meeting the requirement of one-third of the total board members[112]. - The company has a dedicated internal audit department to oversee daily operations and major related transactions[114]. - The company has established a clear organizational structure to prevent fraud risks through separation of incompatible duties[162]. - The company has made provisions for bad debts based on prudence principles at the end of the reporting period[105]. Environmental Responsibility - The company has maintained compliance with environmental regulations, but future changes in laws may increase environmental costs[106]. - The company has implemented advanced environmental management technologies to reduce carbon emissions, improving fuel utilization efficiency and reducing CO2 emissions[179]. - The company has established a management system for energy efficiency and carbon emission reduction[179]. - The company has a solid waste management system in place, including the collection and recycling of waste packaging materials and the disposal of hazardous waste by qualified units[176]. - The company conducts annual emergency response training and drills as part of its environmental incident emergency plan[177]. Employee and Stakeholder Relations - The company has a total of 261 production personnel, 382 sales personnel, and 175 technical personnel[151]. - The company has established a salary system based on employee contributions, with performance-based compensation for market personnel[152]. - Employee rights are protected through a competitive compensation system and a focus on employee health and corporate culture[181]. - The company has implemented a stock incentive plan for its executives, which is expected to align their interests with those of shareholders[122]. - The management team emphasizes a commitment to sustainability, with plans to implement eco-friendly practices in production by 2023[132]. Risk Management - The company acknowledges the risks associated with drug development, including long cycles and high costs, and is committed to improving R&D efficiency and protecting intellectual property[104]. - The company has implemented measures to control accounts receivable risk, including enhancing the assessment of the business operation center and monitoring the entire sales process[105]. - The company has established a risk response strategy based on its strategic goals and development needs[162]. - The company has actively engaged with stakeholders to balance interests and promote sustainable development[115]. - The company has made improvements to its internal control system to adapt to changing external environments and internal management requirements[162].